NEW YORK – Fluxergy said Thursday that it had acquired certain employees, assets, and licensed decentralized blood testing technology from InnaMed in a deal that will help Fluxergy develop a rapid basic metabolic panel.
Irvine, California-based Fluxergy said it will incorporate blood testing startup InnaMed's decentralized electrochemical biosensor technology into Fluxergy's sample-to-answer microfluidic testing platform. The existing Fluxergy Analyzer incorporates fluorescence, colorimetry, electrical potentiometry, and imaging cytometry, and Philadelphia-based InnaMed's technology will add the abilities to detect small molecules and clinical chemistries in human and veterinary medicine.
Financial and other terms of the deal were not disclosed.
Fluxergy President Tej Patel said in a statement the acquisition helps his company fulfill a vision of giving clinicians, healthcare providers, and laboratory professionals access to basic and specialized laboratory tests through a single decentralized platform. Electrochemical tests can be used to detect biomarkers including glucose, electrolytes, hormones, liver proteins, and cardiac proteins, and Fluxergy said assay developers can use the company's point-of-care platform to integrate custom assays.